Neurana Pharmaceuticals, Inc. is a San Diego based, privately held, late clinical stage biotechnology company. Recognizing the potential of a strong drug candidate successfully being used elsewhere in the world, Neurana formed a team of experienced biotech executives committed to bringing a better version of the therapy to patients in the United States suffering from neuromuscular conditions.
In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth, and Longitude Capital.
